In patients with TGs >150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%.

Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk.

Proud to be a part of this team.

Full paper now in NEJM.

TIMI Study Group Brian Bergmark

#SGLT2i Following Acute Myocardial Infarction: The #DAPA -MI and #EMPACT -MI Trials

jacc.org/doi/abs/10.101… #ACC24 Alexander Peikert Muthu Vaduganathan JACC Journals

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC

#ACC24

#ACC2024  LBT: AEGIS-II
➡️4 weekly infusions of ApoA-1 vs placebo to improve cholesterol efflux after MI
🌎18,219 high-risk AMI pts wMVD (50% STEMI, 88% PCI)
💔No differences in primary endpoint at 90 days
🎯MACE, CVdeath/MI reduced in pts with LDL>100
NEJM C. Michael Gibson MD #ACC24

#ACC24 #JACC SimPub: New from #PARADIGMHF - #ARNI exhibits consistent safety and efficacy across the continuum of #KDIGO kidney risk. bit.ly/3J8z5hv

#HFrEF #CKD Safia Chatur, MD Iris Beldhuis scottdavidsolomon Muthu Vaduganathan University of Glasgow Heart Failure Research Group

DanGer Shock: Routine implantation of Impella CP on top of standard care is superior to standard care alone in reducing 6-month mortality among patients presenting w/ #STEMI & cardiogenic shock, despite a higher risk of complications. 🔗 bit.ly/3VOcLRG

#ACC24

Presented today at #ACC24 :

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

#ACC24 #JACC LBCT SimPub: In #EMPACT -MI, #cvMI complicated by LV dysfxn or congestion portended a worse prognosis. Regardless of LV dysfxn severity or presence/absence of congestion, empagliflozin ⬇️ both first & total HF hospitalizations but not mortality in EMPACT-MI trial

In AEGIS-II, a trial involving patients with acute myocardial infarction and multivessel coronary artery disease, administration of CSL112, aimed at enhancing HDL function, did not result in a lower risk of myocardial infarction, stroke, or cardiovascular death compared to

ULTIMATE-DAPT results presented at #ACC24

In EMPACT-MI, a randomized trial involving 6522 patients post-acute myocardial infarction, empagliflozin did not significantly reduce the combined outcome of heart failure hospitalization or death compared to placebo over a period of 17.9 months.

Once again, a drug that

Do we have a new option in the treatment of #CardShock related to #AMI ?
Past ACVC President Christian Hassager together with Prof. Jacob E Moeller just published the long awaited results of the DanGer Shock trial #ACC24
⬇️ mortality #MCS vs standard care alone

nejm.org/doi/full/10.10…

Rate and Cause of Sudden Cardiac Death in the Young During the COVID-19 Pandemic and Vaccination | Circulation ahajournals.org/doi/10.1161/CI…

How I use #ultrasound in cardiac arrest
🫀 #POCUS to confirm CA & guide management during cardiopulmonary resuscitation
🚨general assessment immediately after ROSC: hemodynamics & circulatory support + non cardiac
🔮 future perspective
#FOAMcc #FOAMus
🔓rdcu.be/dsrQ8
🧵

𝐃𝐢𝐬𝐭𝐢𝐥𝐥𝐚𝐭𝐢 𝐝𝐢 𝐛𝐮𝐨𝐧𝐬𝐞𝐧𝐬𝐨 ⚗️
🎥💊 𝐺𝑢𝑎𝑟𝑑𝑎 𝑙’𝑢𝑙𝑡𝑖𝑚𝑎 𝑣𝑖𝑑𝑒𝑜𝑝𝑖𝑙𝑙𝑜𝑙𝑎 '𝐐𝐮𝐚𝐧𝐝𝐨 𝐢𝐧 𝐔𝐂𝐈𝐂 𝐥𝐚 𝐬𝐢𝐭𝐮𝐚𝐳𝐢𝐨𝐧𝐞… 𝐬𝐜𝐨𝐭𝐭𝐚' 𝑎 𝑐𝑢𝑟𝑎 𝑑𝑒𝑙 𝐷𝑜𝑡𝑡𝑜𝑟 𝐍𝐢𝐜𝐨𝐥𝐚 𝐆𝐚𝐬𝐩𝐚𝐫𝐞𝐭𝐭𝐨
👉 lnkd.in/dJ6YaU9A

🧵/ Late breaking science results from #AHA23 will be posted to this thread at the time of presentation:

SELECT
MINT
ORBITA-2
CRHCP Dementia
POP-HT
KARDIA-1
CARDIA-SSBP
ARTESIA
VERVE-101
ESPRIT
SPEC-AI Nigeria
SPEECH

⬇️

(bookmark this post)

In patients with STEMI and NSTEMI undergoing PCI from the TALOS-AMI trial, switching from ticagrelor to clopidogrel after 1 month reduced bleeding while maintaining protection against thrombotic events in both patients with and without high bleeding risk.
eurointervention.pcronline.com/article/de-esc…

While PCSK9 inhibitors like mAbs (evolocumab, alirocumab), siRNA (inclisiran) and small molecules (bembedoic acid) gain momentum, I'm fascinated and scared by this CRISPR/Cas9 permanent gene editing concept for lowering LDL cholesterol: 'Fire and forget'.
nature.com/articles/s4158…

Il primo prelievo di cuore da donatore cadavere in Italia cardiologianegliospedali.it/il-primo-preli…

👏Happy to announce to #CardioTwitter friends that Giornale Italiano di Cardiologia has an #ImpactFactor , thanks to the great work of the Editor Di Pasquale and the many professionals who contribute to a quality 🇮🇹 journal🌟
Pensiero Scientifico
Ciro Indolfi
Marino Scherillo
Leonardo De Luca, MD, PhD, FACC, FESC
Gianluca Campo